|1.||Liu, Yang: 2 articles (01/2014 - 04/2010)|
|2.||Peng, Shan-Ying: 1 article (01/2014)|
|3.||Zhang, Hai-Jing: 1 article (01/2014)|
|4.||Wu, Lian-Qiu: 1 article (01/2014)|
|5.||Han, Wen-Yang: 1 article (01/2014)|
|6.||Wang, Wen-Jie: 1 article (01/2014)|
|7.||Wang, Lin: 1 article (04/2010)|
|8.||Wang, Wen-jie: 1 article (04/2010)|
|9.||Peng, Shan-ying: 1 article (04/2010)|
|10.||Li, Ping: 1 article (04/2010)|
|1.||Pulmonary Fibrosis (Hamman Rich Syndrome)
01/01/2014 - "These findings demonstrated that SY0916 could possibly be developed as a promising candidate for the treatment of pulmonary fibrosis. "
01/01/2014 - "The inhibition effect and mechanism of SY0916 on pulmonary fibrosis."
01/01/2014 - "In this study, the inhibitory effect of SY0916 on pulmonary fibrosis was investigated in epithelial-mesenchymal transition (EMT) induced by transforming growth factor beta 1 (TGF-β1) in vitro and a pulmonary fibrosis animal model induced by bleomycin (BLM). "
01/01/2014 - "In vivo, SY0916 administration significantly ameliorated the BLM-mediated histological changes, reduced main biochemical parameters related to pulmonary fibrosis such as hydroxyproline and glutathione, and also notably attenuated the expression of key pro-fibrotic mediator, TGF-β1. "
|1.||Transforming Growth Factor beta (TGF-beta)
|3.||Hydroxyproline (4 Hydroxyproline)
|4.||Glutathione (Reduced Glutathione)